[
  {
    "ts": null,
    "headline": "AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT",
    "summary": "Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m. PT on Wednesday, Feb. 18, 2026. Jean-Charles Soria, senior vice president of oncology within global development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
    "url": "https://finnhub.io/api/news?id=6408741603f553e178df4dbc40ce7efe33cf0121b7937ab2422824608c18d15b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771016460,
      "headline": "AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT",
      "id": 139089726,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m. PT on Wednesday, Feb. 18, 2026. Jean-Charles Soria, senior vice president of oncology within global development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
      "url": "https://finnhub.io/api/news?id=6408741603f553e178df4dbc40ce7efe33cf0121b7937ab2422824608c18d15b"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Files For Mixed Shelf Offering; Size Not Disclosed",
    "summary": "https://www.sec.gov/Archives/edgar/data/318154/000119312526051627/d55489ds3asr.htm",
    "url": "https://finnhub.io/api/news?id=6dec584be6caedaa5bda9718507209d5abe80b36f65e92a9cd79a1045326ed46",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771005007,
      "headline": "Amgen Files For Mixed Shelf Offering; Size Not Disclosed",
      "id": 139096260,
      "image": "",
      "related": "AMGN",
      "source": "Benzinga",
      "summary": "https://www.sec.gov/Archives/edgar/data/318154/000119312526051627/d55489ds3asr.htm",
      "url": "https://finnhub.io/api/news?id=6dec584be6caedaa5bda9718507209d5abe80b36f65e92a9cd79a1045326ed46"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best medical research stocks to buy according to hedge funds. Amgen Inc. (NASDAQ:AMGN) received rating updates from Argus Research and Guggenheim on February 6. Argus reiterated a Buy rating on the stock with a $400 price target, while Guggenheim reaffirmed a Hold rating on Amgen Inc. (NASDAQ:AMGN) and […]",
    "url": "https://finnhub.io/api/news?id=2b8519fa5b1db57542e7ca80e3c8730bad5055f757a8ffbedee97f8f87ca5048",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994663,
      "headline": "Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)",
      "id": 139085093,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best medical research stocks to buy according to hedge funds. Amgen Inc. (NASDAQ:AMGN) received rating updates from Argus Research and Guggenheim on February 6. Argus reiterated a Buy rating on the stock with a $400 price target, while Guggenheim reaffirmed a Hold rating on Amgen Inc. (NASDAQ:AMGN) and […]",
      "url": "https://finnhub.io/api/news?id=2b8519fa5b1db57542e7ca80e3c8730bad5055f757a8ffbedee97f8f87ca5048"
    }
  },
  {
    "ts": null,
    "headline": "Prices, pipelines and patent cliffs: Inside pharma's big reset",
    "summary": "The new year is shaping up to be a defining year following a dramatic 2025, and one where the impact from last year's developments will crystallize.",
    "url": "https://finnhub.io/api/news?id=df96f791cb216e901bf4bc9085f5f034a80bf7fb4792e673d57c7ebe196d4cb9",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770963193,
      "headline": "Prices, pipelines and patent cliffs: Inside pharma's big reset",
      "id": 139085999,
      "image": "https://image.cnbcfm.com/api/v1/image/108204641-1758911651043-gettyimages-2237192235-nazir-notitle250926_np0Hd.jpeg?v=1758911691&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "The new year is shaping up to be a defining year following a dramatic 2025, and one where the impact from last year's developments will crystallize. ",
      "url": "https://finnhub.io/api/news?id=df96f791cb216e901bf4bc9085f5f034a80bf7fb4792e673d57c7ebe196d4cb9"
    }
  },
  {
    "ts": null,
    "headline": "1 Large-Cap Stock Worth Your Attention and 2 We Avoid",
    "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
    "url": "https://finnhub.io/api/news?id=a6168ce4a63dcfb1c52de253a11c014e7ea8a39c8b72ae44413eab922f2861df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770957558,
      "headline": "1 Large-Cap Stock Worth Your Attention and 2 We Avoid",
      "id": 139089727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
      "url": "https://finnhub.io/api/news?id=a6168ce4a63dcfb1c52de253a11c014e7ea8a39c8b72ae44413eab922f2861df"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update",
    "summary": "Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its inflammation and immunology portfolio, discussing expansion plans for UPLIZNA, new phase II results for daxdilimab in discoid lupus, progress in Sjögren’s syndrome studies for dazodalib",
    "url": "https://finnhub.io/api/news?id=36e5ab238da522bbb2f092ed5c9f63f4bf48ae2d55b967a5457335df204373dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770945277,
      "headline": "Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update",
      "id": 139077141,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its inflammation and immunology portfolio, discussing expansion plans for UPLIZNA, new phase II results for daxdilimab in discoid lupus, progress in Sjögren’s syndrome studies for dazodalib",
      "url": "https://finnhub.io/api/news?id=36e5ab238da522bbb2f092ed5c9f63f4bf48ae2d55b967a5457335df204373dd"
    }
  }
]